Nothing Special   »   [go: up one dir, main page]

KR830005872A - Method of preparing interferon for oral administration - Google Patents

Method of preparing interferon for oral administration Download PDF

Info

Publication number
KR830005872A
KR830005872A KR1019810003034A KR810003034A KR830005872A KR 830005872 A KR830005872 A KR 830005872A KR 1019810003034 A KR1019810003034 A KR 1019810003034A KR 810003034 A KR810003034 A KR 810003034A KR 830005872 A KR830005872 A KR 830005872A
Authority
KR
South Korea
Prior art keywords
interferon
species
cells
isolated
heterologous
Prior art date
Application number
KR1019810003034A
Other languages
Korean (ko)
Inventor
주니어 조셉 엠. 컴민스
Original Assignee
원본미기재
유니버시티 오브 일리노이스 화운데이숀
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 원본미기재, 유니버시티 오브 일리노이스 화운데이숀 filed Critical 원본미기재
Publication of KR830005872A publication Critical patent/KR830005872A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/565—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

내용 없음No content

Description

경구투약용 인터페론읠 제조방법Method for preparing interferon 용 for oral administration

본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음Since this is an open matter, no full text was included.

Claims (17)

이종성 종의 인터페론을 생문학적 활성분절들과 연관된 이질적인 폴리펩티드나 탄수화물로부터 실질적으로 벗어난 비종특이성 생물학적 활성분절들이 있는 소화기관에 주입시킨 다음 인터페론의 생물학적 활성분절을 수용동물의 순환계로 투여시키는 것을 특징으로한 이종성 포유동물 종의 세포에서 분리된 인터페론 당단백질의 생물학적 활성분절을 수용포유동물로 투여하는 방법.Interferon of a heterologous species is injected into the digestive tract with non-specific biologically active segments substantially free of heterologous polypeptides or carbohydrates associated with biologic active segments, and then the biologically active segment of interferon is administered to the recipient's circulatory system. A method of administering to a mammalian a biologically active segment of interferon glycoprotein isolated from cells of a heterologous mammalian species. 상기 인터페론을 수용체인 포유동물의 소화관으로 주입시키는 것을 포함한 상기 처리법과 투여단계들로 이루어진 것을 특징으로한 청구범위 제1항에 의한 방법.The method according to claim 1, comprising the treatment and administration steps comprising injecting the interferon into a mammalian gut as a receptor. 상기 처리단계가 실험관내에서 이루어지고 최종적으로 처리된 인터페론이 상기 투여단계로 투여되기 전에 상기 소화기관으로부터 재생된 것을 특징으로한 청구범위 제1항에 의한 방법.The method according to claim 1, wherein said treatment step is carried out in vitro and the finally treated interferon is regenerated from said digestive organs prior to administration to said administration step. 상기의 방법으로 재생한 처리된 인터페론을 비경구적인 투여방밥으로 투여하는 것을 특징으로한 청구범위 제3항에 의한 방법.The method according to claim 3, wherein the treated interferon regenerated by the above method is administered parenterally. 이종성 종의 세포에서 분리된 상기 인터페론이 인간이나 고양이나 소나 이퀸이나 랩프린이나 돼지 종의 세포에서 분리된 것인 청구범위 제1항의 의한 방법.The method according to claim 1, wherein the interferon isolated from cells of heterologous species is isolated from cells of human, cat, cow, equine, labrin, or swine species. 수용체인 포유동물이 인간이나 고양이나 소나 이퀸이나 랩프린이나 돼지 종인 청구범위 제1항에 의한 방법.The method according to claim 1, wherein the mammal as a receptor is a human, a cat, a cow, an queen, a labrin, or a pig species. 이종성 종의 세포에서 분리된 상기 인터페론이 소종의 세포에서 분리된 것이고 수용동물들이 인간이나 고양이 종인 것을 특징으로하는 청구범위 제1항에 의한 방법.The method according to claim 1, wherein the interferon isolated from the cells of the heterologous species is isolated from the cells of the small species and the recipient animals are human or cat species. 상기 인테페논이 섬유아세포의 인터페론인 청구범위 제7항에 의한 방법.The method according to claim 7, wherein the intephenone is an interferon of fibroblasts. 이종성 포유동물 종의 세포에서 분리된 인터페론의 효과적인 양을 수용체인 포유동물의 소화관으로 투여하는 방법에 있어서, 상기 인터페론의 비종특이성인 항부루스성 또는 항신성형술적 분절을 소화관 조직을 통하여 흡착하여 수용동물의 순환계로 운반하는 개선된 방법으로 외생적인 인터페론 당단백질을 비루스성이거나 신성형술적 질병상태로 포유동물의 반응능력을 강화할 필요가 있는 포유동물의 순환계로 공급하는 방법.In a method of administering an effective amount of interferon isolated from cells of a heterologous mammalian species to the digestive tract of a mammal, which is a receptor, an anti-burus or anti-neoplastic segment of the interferon is adsorbed through a digestive tract tissue to receive a mammal. An improved method of transporting the circulatory system of exogenous interferon glycoproteins into the circulatory system of a mammal in need of enhancing the responsiveness of the mammal to a viral or neoplastic disease state. 소화관에 투여한 인테페론의 양은 1회 분량에서 생리학적으로 수락되는 희석제와 보조약 또는 운반체와 결합한 전체무게의 kg당 10-1,000 유닛 정도를 함유한 것을 특징으로 하는 청구범위 제9항에 의한 개선된 방법.The amount of inteferon administered to the digestive tract contains about 10-1,000 units per kg of total weight combined with physiologically acceptable diluents and supplements or carriers in an aliquot of the claim according to claim 9 Way. 이종성 종의 세포에서 분리된 상기 인터페론이 인간이나 고양이나 소나 이퀸이나 랩프린이나 돼지종의 세포에서 분리된 것을 특징으로 하는 청구범위 제9항에 의한 개선된 방법.The improved method according to claim 9, wherein the interferon isolated from cells of heterologous species is separated from cells of human, cat, cow, equine, labrin or porcine species. 수용포유동물이 인간이나 고양이나 소나 이퀸이나 랩프린이나 돼지종인 청구범위 제9항에 의한 개선된 방법.The improved method according to claim 9, wherein the mammal is a human or a cat or a cow or an queen or a laprine or a pig species. 이종성 종의 세포에서 분리된 상기 인터페론이 소의 세포에서 분리된 것이고 수용포유동물이 인각종인 청구범위 제9항에 의한 개선된 방법.The improved method according to claim 9, wherein said interferon isolated from cells of heterologous species is isolated from bovine cells and the mammal is a human species. 상기 인터페론이 섬유아세포 인터페론인 청구범위 제13항에 의한 개선된 방법.The improved method according to claim 13, wherein said interferon is fibroblast interferon. 강화된 반응이 양성유두종 상태에서의 반응인 청구범위 제13항에 의한 개선된 방법.The improved method according to claim 13, wherein the enhanced response is a reaction in benign papilloma condition. 강화된 반응이 악성혹종상태에서의 반응인 청구범위 제13항에 의한 개선된 방법.The improved method according to claim 13, wherein the enhanced response is a response in a malignant seed state. 이종성 종의 세포에서 분리된 상기 인터페론이 소 종의 세포에서 분리된 것이며 수용 포우동물은 고양이 종이며 강화된 반응은 고양이성 백혈병 상태에서의 반응인 청구범위 제9항에 의한 개선된 방법.The improved method according to claim 9, wherein the interferon isolated from the cells of the heterologous species is isolated from the cells of the bovine species, the recipient pouna is a cat species and the enhanced response is a reaction in the feline leukemia state. ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.※ Note: The disclosure is based on the initial application.
KR1019810003034A 1980-08-22 1981-08-20 Method of preparing interferon for oral administration KR830005872A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18046480A 1980-08-22 1980-08-22
US180464 1980-08-22

Publications (1)

Publication Number Publication Date
KR830005872A true KR830005872A (en) 1983-09-14

Family

ID=22660569

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019810003034A KR830005872A (en) 1980-08-22 1981-08-20 Method of preparing interferon for oral administration

Country Status (4)

Country Link
EP (1) EP0058192A1 (en)
JP (1) JPS57501236A (en)
KR (1) KR830005872A (en)
WO (1) WO1982000588A1 (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5827694A (en) * 1982-03-08 1998-10-27 Genentech, Inc. DNA encoding non-human animal interferons, vectors and hosts therefor, and recombinant production of IFN polypeptides
US5831023A (en) * 1982-11-01 1998-11-03 Genentech, Inc. Recombinant animal interferon polypeptides
US4497795A (en) * 1982-12-13 1985-02-05 The Texas A&M University System Method of regulating appetite and efficiency of food utilization employing interferon
US4820515A (en) * 1982-12-13 1989-04-11 Texas A&M University System Method of using interferon in low dosage to regulate appetite and efficiency of food utilization
US4820514A (en) * 1985-12-30 1989-04-11 Texas A&M University System Low dosage of interferon to enhance vaccine efficiency
ZA878295B (en) * 1986-11-06 1988-05-03 Amarillo Cell Culture Co. Inc. Treatment of immuno-resistant disease
CA1320905C (en) * 1986-11-06 1993-08-03 Joseph M. Cummins Treatment of immuno-resistant disease
US5017371A (en) * 1988-01-06 1991-05-21 Amarillo Cell Culture Company, Incorporated Method for reducing side effects of cancer therapy
WO1990007618A1 (en) * 1988-12-28 1990-07-12 Toshiro Suzuki Concrete strut material
AUPN976596A0 (en) * 1996-05-09 1996-05-30 Pharma Pacific Pty Ltd Stimulation of host defence mechanisms
IL126971A0 (en) 1996-05-09 1999-09-22 Pharma Pacific Pty Ltd Interferon compositions
CN1151840C (en) * 1996-05-09 2004-06-02 太平洋制药控股公司 Stimulation of host defence mechanisms against tumors
US6207145B1 (en) 1997-05-09 2001-03-27 Pharma Pacific Pty Ltd. Therapeutic applications of high dose interferon
US6660258B1 (en) 1997-05-09 2003-12-09 Pharma Pacific Pty Ltd Oromucosal cytokine compositions and uses thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK485977A (en) * 1977-11-01 1979-05-02 Ess Foodeksport PROCEDURE FOR EXTRACTING A BIOLOGICAL ACTIVE MATERIAL FROM PIG BLOOD FRACTIONS
JPS5562024A (en) * 1978-10-31 1980-05-10 Hayashibara Takeshi Preventive and remedy for interferon-sensitive disease
ZA796175B (en) * 1978-11-24 1980-11-26 Hoffmann La Roche Purified proteins and process therefor

Also Published As

Publication number Publication date
WO1982000588A1 (en) 1982-03-04
EP0058192A1 (en) 1982-08-25
JPS57501236A (en) 1982-07-15

Similar Documents

Publication Publication Date Title
Scothorne et al. Cellular changes in lymph nodes and spleen following skin homografting in the rabbit
KR830005872A (en) Method of preparing interferon for oral administration
Tomac et al. Retrograde axonal transport of glial cell line-derived neurotrophic factor in the adult nigrostriatal system suggests a trophic role in the adult.
Whitworth et al. Transfer of milk prolactin to the plasma of neonatal rats by intestinal absorption
US4861757A (en) Wound healing and bone regeneration using PDGF and IGF-I
AU600069B2 (en) Wound healing and bone regeneration
US5019559A (en) Wound healing using PDGF and IGF-II
Nakano et al. Effects of bone marrow stromal cell transplantation through CSF on the subacute and chronic spinal cord injury in rats
JPH09504516A (en) Increased hematopoietic progenitor cells in peripheral blood by transforming growth factor-beta
Kuenzi et al. Immunohistochemical localization of specific relaxin-binding cells in the cervix, mammary glands, and nipples of pregnant rats
US5843887A (en) Compositions for delivery of polypeptides, and methods
Beck et al. Hormonal activation of the insect brain
CA2060208C (en) Wound healing
Kupiec-Weglinski et al. Lymphocyte traffic is modified in vivo by anti-laminin antibody.
Alexander et al. Adoptively transferred tumor-infiltrating lymphocytes can cure established metastatic tumor in mice and persist long-term in vivo as functional memory T lymphocytes
Daikoku et al. Ontogenetic appearance of immunoreactive GRF-containing neurons in the rat hypothalamus
Zammit et al. Macrophage response during axonal regeneration in the axolotl central and peripheral nervous system
Costa et al. Characterization of the circadian system in a Brazilian species of monkey (Callithrix jacchus): immunohistochemical analysis and retinal projections
Nicoll Role of prolactin and placental lactogens in vertebrate growth and development
Kumar et al. Fluorescence studies using anti-nerve growth factor
CN111773244B (en) Application of nano iron sulfide mixture in preparation of acute poisoning recovery medicine for ethanol
Yao et al. Effect of mesenchymal stem cell-incorporated hydroxyapatite-collagen scaffold on tissue repair in acute spinal cord injury, and the mechanism involved
Martin et al. Thyroidal influence on myocardial changes induced by simulated high altitude
Chang et al. A potent dopamine-releasing factor is present in high concentrations in the rat adrenal gland
CA1329122C (en) Prevention of bovine respiratory disease complex in cattle by administration of interferon